A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus.

Authors

Yu Zhang, Yueyue Duan, Lei Shi, Xueliang Zhu, Wenquan Mao, Luyao Li, Cong Yuan, Maowen Sun, Juan Zhang, Liyan Cao, Xiangyu Kong, Haixue Zheng, Qi Wang

Published in

Journal of virology. Pages e0119326. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Swine acute diarrhea syndrome coronavirus (SADS-CoV), an emerging bat-derived coronavirus, causes severe diarrhea and mortality in young hosts and exhibits cross-species transmission potential. However, no licensed vaccines are currently available. In this study, we constructed a recombinant pseudorabies virus (PRV) vaccine strain, designated rPRV-SADS-S, which expresses the full-length spike (S) protein of SADS-CoV. This strain was developed based on the PRV Bartha-K61 backbone. In murine models, rPRV-SADS-S induced robust humoral and cellular immune responses against both PRV and SADS-CoV. Immunized mice exhibited complete clinical protection against lethal challenge with PRV. Notably, maternally transferred antibodies provided protection to neonatal mice against lethal SADS-CoV challenge. Moreover, in porcine models, rPRV-SADS-S provided complete clinical protection against lethal PRV challenge in piglets. Immunization of sows with rPRV-SADS-S conferred specific antibodies and neutralizing antibodies against SADS-CoV in newborn piglets and enabled them to resist SADS-CoV challenge. These results demonstrate that rPRV-SADS-S functions as a dual-target vaccine candidate, effectively mitigating the threats posed by both PRV and SADS-CoV.
Throughout history, pandemics have vividly demonstrated the reality of animal coronaviruses spilling over into human populations. This situation urgently necessitates the formulation of proactive countermeasures. Although 9 years have passed since SADS-CoV emerged in swine, there are still no licensed vaccines against this bat-derived coronavirus. To address this critical gap, we utilized the PRV Bartha-K61 vector platform to develop a novel bivalent vaccine. This strategic approach not only provides concurrent protection against PRV, a significant porcine pathogen, but also induces protective immunity against SADS-CoV. Our strategy potentially mitigates zoonotic spillover risks to humans, thereby offering a vital tool for One Health preparedness.

PMID:
42831625
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.